Comment
. 2006 Oct 1;24(28):4669-70; author reply 4670-1.
doi: 10.1200/JCO.2006.08.1026.
Problems with the randomized discontinuation design
- PMID: 17008711
- DOI: 10.1200/JCO.2006.08.1026
Item in Clipboard
Comment
Problems with the randomized discontinuation design
J Clin Oncol.
.
No abstract available
Comment on
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24. J Clin Oncol. 2006. PMID: 16636341 Clinical Trial.
Similar articles
-
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.J Clin Oncol. 2008 Jul 10;26(20):3469-71; author reply 2471. doi: 10.1200/JCO.2008.17.7410. J Clin Oncol. 2008. PMID: 18612169 No abstract available.
-
Targeting renal cell carcinoma.J Clin Oncol. 2009 Jul 10;27(20):3274-6. doi: 10.1200/JCO.2009.21.8461. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451422 No abstract available.
-
Biomarkers in renal cell carcinoma: what next?Curr Oncol Rep. 2011 Apr;13(2):87-9. doi: 10.1007/s11912-011-0155-2. Curr Oncol Rep. 2011. PMID: 21271363 No abstract available.
-
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.Clin Cancer Res. 2007 Jul 1;13(13):3765-70. doi: 10.1158/1078-0432.CCR-06-2844. Clin Cancer Res. 2007. PMID: 17606705 Review. No abstract available.
-
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Nihon Jinzo Gakkai Shi. 2012. PMID: 22991835 Review. Japanese. No abstract available.
Cited by
-
Fool's gold, lost treasures, and the randomized clinical trial.BMC Cancer. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193. BMC Cancer. 2013. PMID: 23587187 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
